Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 21, 2007, Pages 6692-6704

  Asaki, Tetsuo ^a   Hamamoto, Taisuke ^a   Sugiyama, Yukiteru ^a   Kuwano, Keiichi ^a   Kuwabara, Kenji ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Antiaggregatory activity; Diphenylpyrazine; IP receptor agonist; Prostacyclin

Indexed keywords

2 [4 [(5,6 DIPHENYLHYDRAZIN 2 YL)(ISOPROPYL)AMINO]BUTOXY] N (METHYLSULFONYL)ACETAMIDE; 3 [[(5,6 DIPHENYLPYRAZIN 2 YL)(METHYL)AMINO]ETHYL]PHENOXY ACETIC ACID; 3 [[(5,6 DIPHENYLPYRAZIN 2 YL)(METHYL)AMINO]METHYL]PHENOXY ACETIC ACID; 4 (5,6 DIPHENYLHYDRAZIN 2 YLSULFONYL)BUTOXY ACETIC ACID; 4 (5,6 DIPHENYLPYRAZIN 2 YLOXY)BUTOXY ACETIC ACID; 4 (5,6 DIPHENYLPYRAZIN 2 YLSULFANYL)BUTOXY ACETIC ACID; 4 (5,6 DIPHENYLPYRAZIN 2 YLSULFINYL)BUTOXY ACETIC ACID; 4 [(5,6 DIPHENYLPYRAZIN 2 YL)(ETHYL)AMINO]BUTOXY ACETIC ACID; 4 [(5,6 DIPHENYLPYRAZIN 2 YL)(ISOPROPYL)AMINO]BUTOXY ACETIC ACID; 4 [(5,6 DIPHENYLPYRAZIN 2 YL)(METHYL)AMINO]BUTOXY ACETIC ACID; 4 [(ALLYL)(5,6 DIPHENYLPYRAZIN 2 YL)AMINO]BUTOXY ACETIC ACID; 4 [(BENZYL)(5,6 DIPHENYLPYRAZIN 2 YL)AMINO]BUTOXY ACETIC ACID; 4 [(CYCLOPENTYL)(5,6 DIPHENYLHYDRAZIN 2 YL)AMINO]BUTOXY ACETIC ACID; 4 [(CYCLOPENTYL)(5,6 DIPHENYLPYRAZIN 2 YL)AMINO]BUTOXY ACETIC ACID; 4 [(CYCLOPROPYL) (5,6 DIPHENYLPYRAZIN 2 YL)AMINO]BUTOXY ACETIC ACID; 4 [(CYCLOPROPYL)(5,6 DIPHENYLPYRAZIN 2 YL)AMINO]BUTOXY ACETIC ACID; 5 [4 [(5,6 DIPHENYLHYDRAZIN 2 YL)(ISOPROPYL)AMINO]BUTOXYMETHYL] 1H TETRAZOLE; 6 [(5,6 DIPHENYLPYRAZIN 2 YL)(METHYLAMINO]HEXANOIC ACID; 7 [(5,6 DIPHENYLPYRAZIN 2 YL)(METHYL)AMINO]HEPTANOIC ACID; 8 [(5,6 DIPHENYLPYRAZIN 2 YL)(METHYL)AMINO]OCTANOIC ACID; BERAPROST; BMY 42393; DIPHENYLPYRAZINE DERIVATIVE; OCTIMIBATE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PYRAZINE DERIVATIVE; TERT BUTYL[4 (5,6 DIPHENYLHYDRAZIN 2 YLOXY)BUTOXY]ACETIC ACID; TERT BUTYL[4 (5,6 DIPHENYLPYRAZIN 2 YLSULFANYL)BUTOXY]ACETIC ACID; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG POTENCY; IC 50; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

HUMANS; PYRAZINES; RECEPTORS, EPOPROSTENOL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548534420     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.08.010     Document Type: Article

References (27)

1. Moncada S., Gryglewski R., Bunting S., and Vane J.R. Nature 263 (1976) 663
2. Moncada S., and Vane J.R. Pharmacol. Rev. 30 (1978) 293
3. Negishi M., Sugimoto Y., and Ichikawa A. Prog. Lipid Res. 32 (1993) 417
4. Ohno K., Nagase H., Matsumoto K., Nishigama H., and Nishio S. Adv. Prostaglandins Thromboxane Leukotriene Res. 15 (1985) 279
5. Toda N. Cardiovasc. Drug Rev. 6 (1988) 222
6. Demolis J.L., Robert A., Mouren M., Funck-Brentano C., and Jaillon P. J. Cardiovasc. Pharmacol. 22 (1993) 711
7. Seiler S.M., Brassard C.L., Arnold A.J., Meanwell N.A., Fleming J.S., and Keely Jr. S.L. J. Pharmacol. Exp. Ther. 255 (1990) 1021
8. Meanwell N.A., Rosenfeld M.J., Trehan A.K., Wright J.J.K., Brassard C.L., Buchanan J.O., Federici M.E., Fleming J.S., Gamberdella M., Zavoico G.B., and Seiler S.M. J. Med. Chem. 35 (1992) 3483
9. Meanwell N.A., Rosenfeld M.J., Trehan A.K., Romine J.L., Wright J.J.K., Brassard C.L., Buchanan J.O., Federici M.E., Fleming J.S., Gamberdella M., Zavoico G.B., and Seiler S.M. J. Med. Chem. 35 (1992) 3498
10. Meanwell N.A., Romine J.L., Rosenfeld M.J., Martin S.W., Trehan A.K., Wright J.J.K., Malley M.F., Gougoutas J.Z., Brassard C.L., Buchanan J.O., Federici M.E., Fleming J.S., Gamberdella M., Hartl K.S., Zavoico G.B., and Seiler S.M. J. Med. Chem. 36 (1993) 3884
11. Hamanaka N., Takahashi K., Nagao Y., Torisu K., Tokumoto H., and Kondo K. Bioorg. Med. Chem. Lett. 5 (1995) 1083
12. Hattori K., Tabuchi S., Okitsu O., and Taniguchi K. Bioorg. Med. Chem. Lett. 13 (2003) 4277
13. Hattori K., Tanaka A., Okitsu O., Tabuchi S., Taniguchi K., Nishio M., Koyama S., Higaki M., Seki J., and Sakane K. Bioorg. Med. Chem. Lett. 15 (2005) 3091
14. Meanwell N.A., Rosenfeld M.J., Wright J.J.K., Brassard C.L., Buchanan J.O., Federici M.E., Fleming J.S., and Seiler S.M. J. Med. Chem. 35 (1992) 389
15. Karmas G., and Spoerri P.E. J. Am. Chem. Soc. 74 (1952) 1580
16. Li A.-H., Moro S., Forsyth N., Melman N., Ji X.-D., and Jacobson K.A. J. Med. Chem. 42 (1999) 706
17. Pietraszkiewicz M., and Jurczak J. Tetrahedron 40 (1984) 2967
18. Wang C., Delcros J.-G., Cannon L., Konate F., Carias H., Biggerstaff J., Gardner R.A., and Phanstiel IV O. J. Med. Chem. 46 (2003) 5129
19. Yardley J.P., and Fletcher H. Synthesis (1976) 244
20. Anderson W.K., McPherson Jr. H.L., New J.S., and Rick A.C. J. Med. Chem. 27 (1984) 1321
21. Ohta A., Okimura K., Tonomura Y., Ohta M., Yasumuro N., Fujita R., and Shimazaki M. Heterocycles 27 (1988) 261
22. Skuballa W., Schillinger E., Stürzebecher C.-S., and Vorbrüggen H. J. Med. Chem. 29 (1986) 313
23. Matassa V.G., Maduskuie Jr. T.P., Shapiro H.S., Hesp B., Snyder D.W., Aharony D., Krell R.D., and Keith R.A. J. Med. Chem. 33 (1990) 1781
24. Gallant M., Carrière M.C., Chateauneuf A., Denis D., Gareau Y., Godbout C., Greig G., Juteau H., Lachance N., Lacombe P., Lamontagne S., Metters K.M., Rochette C., Ruel R., Slipetz D., Sawyer N., Tremblay N., and Labelle M. Bioorg. Med. Chem. Lett. 12 (2002) 2583
25. Kuwano K., Hashino A., Asaki T., Hamamoto T., Yamada T., Okubo K., and Kuwabara K. J. Pharmacol. Exp. Ther. 322 (2007) 1181
26. Watanabe T., Tanaka Y., Sekiya K., Akita Y., and Ohta A. Synthesis (1980) 39
27. Born G.V.R. Nature 194 (1962) 927